報價延遲最少15分鐘:2025/04/13 01:46 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.5476 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.56/0.95
|
|
企業價值
63.57M
|
| 資產負債 |
|
每股賬面淨值
0.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/13 01:46 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent beingdeveloped for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494. |